Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2101-2106

  Doddangoudar, V C ^a   O'donoghue, M M ^a   Chong, E Y C ^b   Tsang, D N C ^b   Boost, M V ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

RpoB; Two component systems; VISA; VraSR graSR

Indexed keywords

BACTERIAL PROTEIN; PROTEIN GRAR; PROTEIN VRAS; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; GENE SEQUENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STOP CODON; VANCOMYCIN NON SUSCEPTIBLE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CODON, NONSENSE; CODON, TERMINATOR; DNA MUTATIONAL ANALYSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; MUTATION, MISSENSE; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84865374293     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks171     Document Type: Article

References (12)

1. Howden BP, Davies JK, Johnson PD et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
2. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
3. Neoh HM, Cui L, Yuzawa H et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycinintermediate resistance. Antimicrob Agents Chemother 2008; 52: 45-53.
4. Cui L, Neoh HM, Shoji M et al. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 1231-4.
5. Doddangoudar VC, Boost MV, Tsang DNC et al. Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical isolate. Clin Microbiol Infect 2011; 17: 1268-72.
6. Watanabe Y, Cui L, Katayama Y et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 2680-4.
7. Doddangoudar VC, O'Donoghue MM, Boost MV et al. Rapid detection of vancomycin non-susceptible Staphylococcus aureus using the spiral gradient endpoint technique. J Antimicrob Chemother 2010; 65: 2368-72.
8. Moreira B, Boyle-Vavra S, de Jonge BL et al. Increased production of penicillin-binding protein 2, increased detection of other penicillinbinding proteins and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1788-93.
9. Maki H, McCallum N, Bischoff M et al. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 1953-9.
10. Sader HS, Jones RN, Rossi KL et al. Occurrence of vancomycin-tolerant and heterogeneous vancomycin intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 2009; 64: 1024-8.
11. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: 1-38.
12. Bhateja P, Purnapatre K, Dube S et al. Characterisation of laboratorygenerated vancomycin intermediate resistant Staphylococcus aureus strains. Int J Antimicrob Agents 2006; 27: 201-11.